New prostate drug delivered directly to target
NCT ID NCT07264205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called RT-310 for men with enlarged prostate (BPH) who have bothersome urinary symptoms. RT-310 is a drug delivered directly into the prostate to reduce side effects. The study will check if it is safe and feasible in 20 men aged 50 to 80.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RT-310 (a drug delivered directly to the prostate)
- What this could lead to
- If it works, this could lead to a new treatment for BPH that reduces side effects by targeting the prostate directly.
- What could go wrong
- This is a very early, small study (20 men) focused only on safety and feasibility. It may not show clear benefit, and the approach might not work in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BPH (BENIGN PROSTATIC HYPERPLASIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Santo Domingo, Dominican Republic
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Needle-Free prostate treatment match implant surgery?
- Can sound waves offer a lasting fix for prostate problems?
- Robotic precision could transform prostate surgery
- Can a disposable scope make prostate surgery faster and cheaper?
- Leg patch may ease bladder troubles after prostate surgery
- Can a simple score predict prostate surgery success?